Malan SF - Search Results

1

Structure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor.

Geldenhuys WJ, Malan SF, Bloomquist JR, Van der Schyf CJ. Geldenhuys WJ, et al. Among authors: malan sf. Bioorg Med Chem. 2007 Feb 1;15(3):1525-32. doi: 10.1016/j.bmc.2006.09.060. Epub 2006 Sep 29. Bioorg Med Chem. 2007. PMID: 17157509

2

Enantiomeric resolution of the calcium channel antagonist 8-benzylamino-8,11-oxapentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]unde cane (NGP 1-01).

Malan SF, Dockendolf G, Van der Walt JJ, van Rooyen JM, van der Schyf CJ. Malan SF, et al. Pharmazie. 1998 Dec;53(12):859-62. Pharmazie. 1998. PMID: 9879570

3

Structure-activity relationships of polycyclic aromatic amines with calcium channel blocking activity.

Malan SF, Van der Walt JJ, Van der Schyf CJ. Malan SF, et al. Arch Pharm (Weinheim). 2000 Jan;333(1):10-6. doi: 10.1002/(sici)1521-4184(200001)333:1<10::aid-ardp10>3.0.co;2-5. Arch Pharm (Weinheim). 2000. PMID: 10675984

4

Screening of novel pentacyclo-undecylamines for neuroprotective activity.

Geldenhuys WJ, Terre'Blanche G, Van der Schyf CJ, Malan SF. Geldenhuys WJ, et al. Among authors: malan sf. Eur J Pharmacol. 2003 Jan 1;458(1-2):73-9. doi: 10.1016/s0014-2999(02)02701-2. Eur J Pharmacol. 2003. PMID: 12498909

5

The structure and ion channel activity of 6-benzylamino-3-hydroxyhexa-cyclo[6.5.0.0(3,7).0(4,12).0(5,10).0(9,13]tridecane.

Malan SF, Dyason K, Wagenaar B, Van Der Walt JJ, Van Der Schyf CJ. Malan SF, et al. Arch Pharm (Weinheim). 2003 Apr;336(2):127-33. doi: 10.1002/ardp.200390009. Arch Pharm (Weinheim). 2003. PMID: 12761766

6

Physicochemical prediction of a brain-blood distribution profile in polycyclic amines.

Zah J, Terre'Blanche G, Erasmus E, Malan SF. Zah J, et al. Among authors: malan sf. Bioorg Med Chem. 2003 Aug 15;11(17):3569-78. doi: 10.1016/s0968-0896(03)00365-1. Bioorg Med Chem. 2003. PMID: 12901901

7

Synthesis and biological evaluation of pentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecane derivatives as potential therapeutic agents in Parkinson's disease.

Geldenhuys WJ, Malan SF, Murugesan T, Van der Schyf CJ, Bloomquist JR. Geldenhuys WJ, et al. Among authors: malan sf. Bioorg Med Chem. 2004 Apr 1;12(7):1799-806. doi: 10.1016/j.bmc.2003.12.045. Bioorg Med Chem. 2004. PMID: 15028270

8

Pharmacology and structure-activity relationships of bioactive polycyclic cage compounds: a focus on pentacycloundecane derivatives.

Geldenhuys WJ, Malan SF, Bloomquist JR, Marchand AP, Van der Schyf CJ. Geldenhuys WJ, et al. Among authors: malan sf. Med Res Rev. 2005 Jan;25(1):21-48. doi: 10.1002/med.20013. Med Res Rev. 2005. PMID: 15389731 Review.

9

Fluorescent ligands for the histamine H2 receptor: synthesis and preliminary characterization.

Malan SF, van Marle A, Menge WM, Zuliani V, Hoffman M, Timmerman H, Leurs R. Malan SF, et al. Bioorg Med Chem. 2004 Dec 15;12(24):6495-503. doi: 10.1016/j.bmc.2004.09.018. Bioorg Med Chem. 2004. PMID: 15556766

10

Effect of polycyclic cage amines on the transmembrane potential of neuronal cells.

Grobler E, Grobler A, Van der Schyf CJ, Malan SF. Grobler E, et al. Among authors: malan sf. Bioorg Med Chem. 2006 Feb 15;14(4):1176-81. doi: 10.1016/j.bmc.2005.09.042. Epub 2005 Oct 24. Bioorg Med Chem. 2006. PMID: 16249094

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

77 results

Search Page

Filters